Skip to main content
. 2024 Nov 6;16(22):3752. doi: 10.3390/cancers16223752

Table 3.

Results from univariate and multivariate logistic regression analyses.

Univariate Multivariate
Variable OR (95% CI) OR (95% CI)
Age at start of adjuvant therapy (yrs) 0.99 (0.94–1.04)
Stage of Disease
I or II 1 (ref) 1(ref)
III 23.33 (4.86–179.29) ** 22.64 (3.59–256.25) **
Lymph Node Status
pN negative 1 (ref)
pN positive 6.79 (1.73–34.82) **
Tumor Size (at Diagnosis) §
pT1 or pT2 1 (ref)
pT3 or pT4 - -
Tumor Histology
Ductal carcinoma 1 (ref)
Lobular carcinoma 0.58 (0.03–6.51)
Other 1.16 (0.04–30.63)
Histologic Grade
1 1 (ref)
2 0.56 (0.02–16.14)
3 1.00 (0.04–27.00)
Ki-67
<20% 1 (ref)
≥20% 0.94 (0.27–3.30)
ER
Negative 1 (ref)
Positive 0.97 (0.27–3.62)
PgR
Negative 1 (ref)
Positive 0.96 (0.29–3.17)
Adjuvant Chemotherapy §
Anthracyclines and taxanes 1 (ref)
Taxanes only 5.33 (0.08–46.61)
Anthracyclines only 0.76 (0.10–4.32)
Other (endocrine therapy, CMF, vinorelbine) - -
BMI at start of Adjuvant Chemotherapy 1.21 (1.03–1.45) * 1.25 (0.99–1.65)
HDAC6 ¥ 16.49 (2.58–164.10) ** 32.78 (2.65–973.27) *
HDAC6 † 2.55 (1.37–5.47) 3.20 (1.38–9.91)
WNT4 ¥ 0.93 (0.55–1.54)
BMPR2 ¥ 7.38 (1.19–64.35) *
PALB2 ¥ 0.72 (0.15–3.16)
PARP1 ¥ 2.55 (0.73–10.20) 0.157

OR: odds ratio; CI: confidence interval; ER: estrogen receptor; PgR: progesterone receptor; BMI: body mass index; CMF: Cyclophosphamide, Methotrexate, Fluorouracil. ** p-value < 0.01; * p-value < 0.05. § Due to the presence of zero cells, the ORs were not computed. ¥ Reported as log2 transformed variable. † Reported as log2 transformed variable and multiplied by 3. The associated odds ratio then is for a 1/3-unit increase in log2 transformed HDAC6. The p-value is the same as log2 transformed only variable.